Takeda Pharma denied general conditional reimbursement in Denmark

The Danish Medicines Agency has rejected Takeda Pharma’s application for general conditional reimbursement for insomnia treatment Slenyto.
Photo: Hannibal Hanschke/Reuters/Ritzau Scanpix
Photo: Hannibal Hanschke/Reuters/Ritzau Scanpix
by christian bundgaard, translated by daniel pedersen

Takeda Pharma’s insomnia drug Slenyto (melatonin) will not be getting general conditional reimbursement in Denmark, according to a recent decision by the Danish Medicines Agency.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading